Sanofi
Brief description of study
The dupilumab clinical program in EoE has provided evidence that long-term suppression of IL-4 and IL-13 could lead to progressive improvement in fibrostenosis. . There is a need for longer term assessments with comprehensive functional, histological, molecular, clinical, and endoscopic assessments to characterize the risk of fibrotic progression as well the potential for reversal with dupilumab.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
